Show notes
Eli Lilly has filed lawsuits against multiple US companies for allegedly selling black market retatrutide and counterfeit GLP products, even before the drug's official 2027 launch. Marcos Rivera and Seamus break down what's driving gray market demand, and why the bigger story isn't the drug itself, it's what health, aesthetics, insurance incentives, and social media are shaping people to believe "better" looks like.
Time Stamps
• 00:00 — Fitflation intro discussion
• 01:20 — Client health scare
• 03:10 — Physique becomes monetized
• 04:05 — Instagram body template
• 05:53 — Podcasting for…

